Swiss National Bank cut its stake in Hologic (NASDAQ:HOLX) by 14.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 884,524 shares of the medical equipment provider’s stock after selling 148,500 shares during the period. Swiss National Bank owned 0.32% of Hologic worth $33,046,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Hologic in the 1st quarter worth approximately $146,000. NuWave Investment Management LLC acquired a new stake in Hologic in the 4th quarter worth approximately $199,000. Fiduciary Trust Co. acquired a new stake in Hologic in the 4th quarter worth approximately $208,000. Advisor Partners LLC acquired a new stake in Hologic in the 4th quarter worth approximately $209,000. Finally, MPS Loria Financial Planners LLC acquired a new stake in Hologic in the 4th quarter worth approximately $214,000. Institutional investors own 98.47% of the company’s stock.
Shares of Hologic opened at $38.98 on Friday, according to Marketbeat Ratings. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 1.13. Hologic has a 12 month low of $37.84 and a 12 month high of $38.15. The company has a market cap of $10.57 billion, a price-to-earnings ratio of 18.61, a price-to-earnings-growth ratio of 1.82 and a beta of 0.87.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, meeting the consensus estimate of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business had revenue of $789.30 million during the quarter, compared to analysts’ expectations of $781.23 million. During the same period in the previous year, the business posted $0.50 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts forecast that Hologic will post 2.24 earnings per share for the current year.
A number of research firms recently commented on HOLX. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Friday, January 19th. BidaskClub cut shares of Hologic from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 25th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Thursday, February 1st. Canaccord Genuity cut shares of Hologic from a “buy” rating to a “hold” rating and lowered their target price for the stock from $48.00 to $39.00 in a research note on Thursday, May 3rd. Finally, Stifel Nicolaus lowered their target price on shares of Hologic from $42.00 to $40.00 and set a “hold” rating for the company in a research note on Thursday, May 3rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $44.87.
In other news, SVP Allison P. Bebo sold 7,000 shares of Hologic stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles J. Dockendorff bought 13,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were purchased at an average cost of $38.80 per share, with a total value of $504,400.00. The disclosure for this purchase can be found here. Insiders own 0.79% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.